Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Atezolizumab

Four-year real-world outcomes of atezolizumab and bevacizumab in HCC
1:32
Four-year real-world outcomes of atezolizumab and bevacizumab in HCC
Julien Edeline • 6 Jul 2026
Superiority of durvalumab versus atezolizumab in extensive-stage SCLC
0:47
Superiority of durvalumab versus atezolizumab in extensive-stage SCLC
Apar Ganti • 12 Jun 2026
Real-world outcomes of atezolizumab and durvalumab in extensive-stage SCLC
0:46
Real-world outcomes of atezolizumab and durvalumab in extensive-stage SCLC
Apar Ganti • 12 Jun 2026
SAAK 06/19: intravesical recombinant BCG plus chemo-IO in MIBC
0:59
SAAK 06/19: intravesical recombinant BCG plus chemo-IO in MIBC
Richard Cathomas • 9 Jun 2026
ctDNA-guided therapy: transforming treatment decisions across tumor types
1:20
ctDNA-guided therapy: transforming treatment decisions across tumor types
Joaquim Bellmunt • 9 Jun 2026
Patient-reported outcomes from IMvigor011: adjuvant atezolizumab in MIBC
2:13
Patient-reported outcomes from IMvigor011: adjuvant atezolizumab in MIBC
Joaquim Bellmunt • 9 Jun 2026
IMbrave251: final analysis of aezolizumab and TKIs in second-line HCC
0:50
IMbrave251: final analysis of aezolizumab and TKIs in second-line HCC
Stephen Lam Chan • 4 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 3 Jun 2026
Real-world survival outcomes with atezolizumab versus durvalumab in extensive-stage SCLC
1:39
Real-world survival outcomes with atezolizumab versus durvalumab in extensive-stage SCLC
Apar Ganti • 2 Jun 2026
Using AI to predict liver decompensation risk in HCC with cirrhosis
3:47
Using AI to predict liver decompensation risk in HCC with cirrhosis
Manon Allaire • 21 Apr 2026
Current PD-(L)1 and VEGF combinations and future bispecifics in NSCLC
4:58
Current PD-(L)1 and VEGF combinations and future bispecifics in NSCLC
Natalie Vokes • 25 Mar 2026
IMvigor011: ctDNA dynamics in MIBC treated with adjuvant atezolizumab
5:02
IMvigor011: ctDNA dynamics in MIBC treated with adjuvant atezolizumab
Joaquim Bellmunt • 3 Mar 2026
SKYSCRAPER-09: atezolizumab and tiragolumab in head and neck cancer
4:14
SKYSCRAPER-09: atezolizumab and tiragolumab in head and neck cancer
Amanda Psyrri • 16 Dec 2025
Systemic therapy & locoregional therapy in intermediate stage HCC
12:53
Systemic therapy & locoregional therapy in intermediate stage HCC
Lorenza Rimassa • 16 Dec 2025
Bladder cancer at ESMO 2025: ALBAN, POTOMAC, CREST, and more
1:45
Bladder cancer at ESMO 2025: ALBAN, POTOMAC, CREST, and more
Felix Guerrero-Ramos • 24 Nov 2025
Redefining patient selection for immunotherapy in MIBC
1:18
Redefining patient selection for immunotherapy in MIBC
Alexander Wyatt • 24 Nov 2025
The content of VJOncology is intended for healthcare professionals